Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 350 of the 371 references it cites were found in a registry or an index; 47 of the 103 sources its claims cite were checked for support.

Diabetic Gastroparesis.

Open access
Bharucha, Adil E, Kudva, Yogish C, Prichard, David O · 2019 · Endocrine Reviews

Abstract

This review covers the epidemiology, pathophysiology, clinical features, diagnosis, and management of diabetic gastroparesis, and more broadly diabetic gastroenteropathy, which encompasses all the gastrointestinal manifestations of diabetes mellitus. Up to 50% of patients with type 1 and type 2 DM and suboptimal glycemic control have delayed gastric emptying (GE), which can be documented with scintigraphy, 13C breath tests, or a wireless motility capsule; the remainder have normal or rapid GE. Many patients with delayed GE are asymptomatic; others have dyspepsia (i.e., mild to moderate indigestion, with or without a mild delay in GE) or gastroparesis, which is a syndrome characterized by moderate to severe upper gastrointestinal symptoms and delayed GE that suggest, but are not accompanied by, gastric outlet obstruction. Gastroparesis can markedly impair quality of life, and up to 50% of patients have significant anxiety and/or depression. Often the distinction between dyspepsia and gastroparesis is based on clinical judgement rather than established criteria. Hyperglycemia, autonomic neuropathy, and enteric neuromuscular inflammation and injury are implicated in the pathogenesis of delayed GE. Alternatively, there are limited data to suggest that delayed GE may affect glycemic control. The management of diabetic gastroparesis is guided by the severity of symptoms, the magnitude of delayed GE, and the nutritional status. Initial options include dietary modifications, supplemental oral nutrition, and antiemetic and prokinetic medications. Patients with more severe symptoms may require a venting gastrostomy or jejunostomy and/or gastric electrical stimulation. Promising newer therapeutic approaches include ghrelin receptor agonists and selective 5-hydroxytryptamine receptor agonists.

Overview

CoChat Summary

TL;DR

This review synthesizes the epidemiology, pathophysiology, clinical features, diagnosis, and management of diabetic gastroparesis and the broader diabetic gastroenteropathy. It emphasizes that delayed gastric emptying is common but often asymptomatic, and that management is guided by symptom severity, degree of emptying delay, and nutritional status.

Key findings

  • Up to 50% of patients with type 1 and type 2 diabetes mellitus and suboptimal glycemic control have delayed gastric emptying; the remainder have normal or rapid emptying. Many with delayed emptying are asymptomatic, while up to 50% of patients have significant anxiety and/or depression.
  • In Olmsted County, the age-adjusted prevalence of definite gastroparesis per 100,000 persons was higher in women (37.8; 95% CI, 23.3–52.4) than men (9.6; 95% CI, 1.8–17.4); 25% of definite, 31% of definite/probable, and 46% of any-definition gastroparesis cases had diabetes.
  • Over 10 years, gastroparesis developed in 5% of type 1 diabetes (HR, 33; 95% CI, 4.0–274 vs controls), 1% of type 2 diabetes (HR, 7.5; 95% CI, 0.8–68), and 1% of controls; risk was greater in type 1 than type 2 diabetes (HR, 4.4; 95% CI, 1.1–17). In the T1D Exchange registry, 4.8% had a clinical diagnosis of gastroparesis, higher in women (5.8%) than men (3.5%).
  • Pathogenesis implicates hyperglycemia, autonomic neuropathy, and enteric neuromuscular inflammation/injury; full-thickness gastric biopsies show loss of interstitial cells of Cajal, loss of enteric nerves, and immune infiltrate, with ICC number correlated with faster 4-hour gastric emptying. Management includes dietary modification, supplemental oral nutrition, antiemetics/prokinetics, and for severe symptoms venting gastrostomy/jejunostomy and/or gastric electrical stimulation; newer approaches include ghrelin receptor agonists and selective 5-hydroxytryptamine receptor agonists.

Methods

  • Narrative review covering epidemiology, pathophysiology, clinical features, diagnosis, and management of diabetic gastroparesis and diabetic gastroenteropathy.
  • Evidence is drawn from cited clinical and population-based studies, including Olmsted County/Rochester Epidemiology Project studies, the T1D Exchange clinic registry, the NIDDK consortium, and the Nationwide Inpatient Sample.
  • Included studies generally defined delayed gastric emptying by objective assessment with scintigraphy, a wireless motility capsule, or a gastric emptying breath test; scintigraphy is described as the criterion standard.

Limitations

  • The paper states that no studies have evaluated the prevalence of delayed gastric emptying among randomly selected community members; population-based studies were based on patients who sought care, and the T1D Exchange diagnostic criteria are unclear. It also notes that Nationwide Inpatient Sample data are not broken down separately for idiopathic and diabetic gastroparesis, and that the extent to which survival is affected by comorbid conditions or gastroparesis severity is unknown.
  • The paper notes that distinguishing dyspepsia from gastroparesis is often based on clinical judgement rather than established criteria, and that it is uncertain whether quality-of-life differences exist between idiopathic and diabetic gastroparesis.
  • Evident from the provided text: the full article is truncated, so later sections on diagnosis and management are not fully available for summary; as a review, it reports no new primary data.

Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/er.2018-00161

Cites

350 of 350 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

37 Valid · 11 Not valid · 40 Not checked · 14 Own results and interpretations

52 more claims · 17 with their cited sources checked

Create a free account to see all 102 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 31
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 371 references

Cited by

See all 252

Metadata

Authors
Bharucha, A. E., Kudva, Y. C., & Prichard, D. O.
Affiliations
Mayo Clinic (US)
Corresponding author
Bharucha, Adil E
Venue
Endocrine Reviews
Published
2019-05-13
Volume
40
Issue
5
Pages
1318-1352
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W4211130106
Cited by
252
References
371
Citations by year
2026: 43 · 2025: 47 · 2024: 39 · 2023: 42 · 2022: 26 · 2021: 33 · 2020: 13 · 2019: 8
FWCI
3.66
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (PO1 DK68055)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
diabetic gastroparesis, delayed gastric emptying, dyspepsia, autonomic neuropathy, hyperglycemia, gastric motility, prokinetic agents, antiemetics, nutritional support, gastric electrical stimulation, ghrelin receptor agonist, serotonin receptor agonists, quality of life, anxiety and depression
MeSH terms
Animals, Diabetic Neuropathies, Female, Humans, Male, Gastroparesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diabetic Gastroparesis. https://app.cochat.ai/papers/10.1210/er.2018-00161
The paper
Bharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019). Diabetic Gastroparesis. Endocrine Reviews. https://doi.org/10.1210/er.2018-00161

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.